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doi:10.1016/j.ejvs.2010.01.016Abstract Background: Patency and limb salvage after synthetic bypass to the arteries below-
knee are inferior to that which can be achieved with autologous vein. Use of a vein collar at the
distal anastomosis has been suggested to improve patency and limb salvage, a problem that is
analysed in this randomised clinical study.
Methods: Patients with critical limb ischaemia undergoing polytetrafluoroethylene (PTFE)
bypass to below-knee arteries were randomly either assigned a vein collar or not in two groups
e bypass to the popliteal artery below-knee (femoro-popliteal below-knee (FemPopBK)) and
more distal bypass (femoro-distal bypass (FemDist)). Follow-up was scheduled until amputa-
tion, death or at most 5 years, whichever event occurred first.
Results: In the FemPopBK and in the FemDist groups, 115/202 and 72/150 were randomised to
have a vein collar, respectively. Information was available for 345 of 352 randomised patients
(98%).
At 3 years, primary patency was 26% (95% confidence interval (CI) 18e38) with a vein collar
and 43 (33e58) without a vein collar for femoro-popliteal bypass and 20 (11e38), and 17
(9e33) for femoro-distal bypass, respectively. The corresponding figures for limb salvage were
64 (54e75) and 61 (50e74) for femoro-popliteal bypass, and 59 (46e76) and 44 (32e61) for
femoro-distal bypass with and without a vein collar, respectively. Log-rank-test for the whole
KaplaneMeier life table curve showed no statistically significant differences with or without
vein collar primary patency: p Z 0.0853, p Z 0.228; secondary patency: p Z 0.317,
p Z 0.280; limb salvage: p Z 0.757, p Z 0.187 for FemPopBK and FemDist, respectively.
The use of a vein collar did not influence patency or limb salvage.efer to the Acknowledgements section in this paper for further details.
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748 SCAMICOSConclusion: This study failed to show any benefit for vein collar with PTFE bypass to a below-
knee artery.
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have inferior patency compared with autologous vein
grafts and most vascular surgeons agree that vein is the
preferred graft conduit for reconstruction at this level.
However, for various reasons, some patients do not have
a suitable vein. The question is how such patients should
be handled when they suffer from critical limb ischaemia
and need a femoro-popliteal below-knee or a femoro-
distal reconstruction. Primary amputation might be
considered1 but it has been suggested that the interposi-
tion of a vein collar at the distal anastomosis can improve
the patency to motivate a reconstruction with a synthetic
graft.2,3
The present prospective randomised clinical study was
designed to evaluate if such an interposed vein collar
actually improves patency and limb salvage in patients
undergoing reconstruction with synthetic polytetrafluoro-
ethylene (PTFE) grafts.Material and Methods
A total of 352 patients with critical limb ischaemia (rest
pain, ulcer or gangrene) scheduled for either femoro-
popliteal below-knee (FemPopBK; n Z 202) or femoro-
distal bypass (FemDist; n Z 150) bypass with a PTFE
graft have been randomly allocated for application of
a vein collar interposed at the distal anastomosis between
the PTFE graft and the recipient artery or a direct anas-
tomosis without vein interposition. The recruitment took
place from 12 January 1995 to 15 June 1998. Three
centres from Denmark and 29 from Sweden participated.
Randomisation was made by means of sealed envelopes.
Packages of envelopes with allocated study arm and
protocols for follow-up were prepared by the study office.
Randomisation packages were made for each participating
centre. It was done separately for patients undergoing
FemPopBK and infra-popliteal reconstruction (FemDist)
(to the anterior or posterior tibial artery, the peroneal
artery or the tibiofibular trunk). Reconstructions to the
foot arteries were not included. For each participating
centre, two packages of randomisation envelopes, one for
FemPopBK (16 envelopes) and the other for FemDist (16
envelopes), were prepared. In each package there was
the same number of allocations to vein collar as to no-
collar patients. When the surgeon had confirmed the
presence of an acceptable recipient artery, an envelope
was picked at random from the appropriate package. For
centres that randomised more than 16 patients in any
group, new packages of the same type were prepared.
Participating vascular units were required to master the
vein collar technique and have the experience of five such
reconstructions before entering the trial. Only patients
with critical ischaemia (rest pain, arterial ulcers or
gangrene) were eligible for the study. Ankle blood pres-
sure was not included in the criteria for critical ischaemia
as they often are falsely high and neither was bloodpressure of the first toe as this method was not available
at all centres.
The type of vein collar used was left to the discretion of
the operating surgeon, and some surgeons used the collar
originally suggested by Miller,2 while others preferred the
‘St. Mary’s boot’4 (reports of vein collar type were available
for 182 of 197 operations (92%) and of these 182 operations,
91 (50%) used the original method). The use of adjuvant
medication to prevent thrombosis of the grafts was also left
to the discretion of the operating surgeon. At 30-day-
follow-up, information concerning the use of anti-platelet
or anticoagulant drugs was available for 235 patients and
was: acetylsalicylic acid: 63.7%, 54.1%; anticoagulant:
16.1%, 22.5%; acetylsalicylic acid combined with anticoag-
ulant: 1.6%, 4.5%; and other anti-platelet or anticoagulant
drug: 4.8%, 8.1% for patients with and without vein collar,
respectively. Thus, 86.3% and 89.2% of the patients with
and without vein collar, respectively, availed of anti-
platelet or anticoagulant medication. A PTFE graft from
either Gore or Impra was used but there was no intention to
compare the two brands. Any diameter of graft was
allowed, the diameter being 6 mm in the vast majority of
operations (6 mm: nZ 303, 5 mm: nZ 13, 8 mm: nZ 2 and
unknown: n Z 25).
Follow-up was scheduled at 1, 3, 6 and 12 months and
thereafter annually for at most 5 years, until amputation of
the limb or death of the patient, whichever event occurred
first.
The Swedish centres (n Z 29) participating in this trial
also performed an independent randomisation of the same
patients to either use an external support of the PTFE graft
or not. The Danish centres (n Z 3) used externally sup-
ported PTFE grafts in all patients. Thus, the randomisation
envelopes for Swedish centres included additional infor-
mation as to whether an externally supported graft should
be used or not. This was set up as a factorial design5 with
equal probability of having external support or not in
addition to a vein collar or not; consequently, 50% of the
patients allocated to a vein collar had external support and
50% of the patients allocated to no-collar did not have
external support. The result of this independent study is to
be published separately.
Hypotheses, power calculation, statistics and ethics
Prior to the study, two primary and four secondary
hypotheses were specified and it was agreed that these
hypotheses should be tested by means of log-rank analysis:6
Primary hypotheses. A ‘vein collar’ at the distal anas-
tomosis in bypass surgery ‘with PTFE’ to the below-knee
popliteal artery (FemPopBK) or infra-popliteal arteries
(FemDist) ‘improves primary patency’.
Secondary hypotheses. A ‘vein collar’ at the distal anas-
tomosis in bypass surgery ‘with PTFE’ to the below-knee
popliteal artery (FemPopBK) or infra-popliteal arteries
(FemDist) ‘improves secondary patency’ and/or ‘limb
salvage’.
Figure 1 Flow chart for 353 patients with critical ischaemia
randomised to vein collar or no vein collar at the distal anas-
tomosis in two groups: FemPopBK (femoro-politeal bypass
below-knee) and FemDist (femoro-distal bypass).
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(above-knee, below-knee or foot) and ‘death’. However,
‘primary occlusion’ (failed primary patency) was the
primary outcome and ‘secondary occlusion’ (failed
secondary patency) and ‘amputation’ (failed limb salvage)
were the secondary outcomes. Graft patency was verified
by the methods used by the various departments recruiting
patients. The methods were angiography, duplex ultraso-
nography, control that an improved ankleebrachial index
(ABI) after operation was maintained during follow-up,
plethysmographic blood flow in the graft, a palpable
pulse over the graft or a bi- or triphasic Doppler signal
detected at two points over the graft. However, report of
the method used to verify an occlusion in an individual
patient was not demanded in the study. ‘Primary patency’
was defined as a patent graft without any intervention to
open up or prevent a graft occlusion. ‘Secondary patency’
was defined as a patent graft after one or several inter-
ventions to open up or prevent a graft occlusion. When
definitive information was available of patency at one point
in time and non-patency at another point in time but there
was no information as to when the occlusion actually did
take place, the midpoint between the two dates was used
as the time point of occlusion.
At the time the study was planned, the 1-year patencies
after PTFE bypass in the SwedVasc Registry were 50% and
40% at 1 year of follow-up for FemPopBK and FemDist,
respectively. In the literature, 75% 1-year primary patency
for FemPopBK with vein collar has been claimed.7 We,
therefore, chose to test for a 50% relative improvement of
primary patency in both the FemPopBK and FemDist groups.
If patency at 1 year after FemPopBK bypass is 50%, an
improvement of 50% (patency 75%) with the help of a vein
collar would require 2  55 Z 110 patients available for
evaluation at 1 year (a Z 0.05 and b Z 0.80). However,
one-fifth of the patients are likely to die during the first
year, which needs to be compensated for with nearly 20
more patients. Thus, 130 patients were required in the
FemPopBK group. If patency at 1 year after FemDist bypass
is 40%, an improvement of 50% (patency 60%) with a vein
collar would require 2  95 Z 190 patients available for
evaluation at 1 year (aZ 0.05 and bZ 0.80). Again, death
during the first year will need compensation with nearly 40
extra patients. Thus, 230 patients were required in the
FemDist group. Two-sided power calculations were used.8
Continuous data were summarised as median (1ste3rd
quartile), categorical data as n/N (percent) and life table
data as percent (95% CI). Differences between categorical
data were tested with the chi2 test9 and differences
between data summarised using KaplaneMeier life table
technique10 were tested with the log-rank test6 for the
whole life table curve. All log-rank analyses were stratified
for the presence or not of external support to eliminate any
possible effect of the variable ‘external support’. Patency
differences between patients with and without a vein collar
at a specific time point were calculated with use of effec-
tive sampling size.11 Interaction between factors was
tested by means of Cox regression.12 All analyses were
made on the basis of intention to treat. Calculations
and analyses were performed with Microsoft Excel
(Microsoft Corporation, Redmond,Washington, USA) and the
R-language.13The study was approved by the Ethics Committee at the
University of Linko¨ping, Sweden and the Scientific Ethics
Committee in the municipalities of Copenhagen and Freder-
iksberg, Denmark. Informed consent was obtained before the
operation and patients were not to be randomised unless an
acceptable recipient artery was available at the operation.
The companies supporting the study did neither have access
to the data nor any influence in preparation of the manu-
script. The reporting standards of ‘The Revised CONSORT
Statement for Reporting Randomised Trials: Explanation and
Elaboration’ have been used for the manuscript.14
Results
Randomisation, missing information and protocol
violations
One female patient was reported to have been randomised
but her further whereabouts, including the group she
belonged to, are not known and she has been excluded in
all subsequent analyses. In the FemPopBK group and in the
FemDist group, 115/202 and 72/150 were randomised to
have a vein collar, respectively. The distribution of the
randomisation was somewhat skewed but not more than
what can be expected by chance (chi2 Z 2.57, df Z 1,
p Z 0.11).
Table 1 Baseline data of randomised and finally analysed patients in the FemPopBK and FemDist bypass groups.a
FemPopBK FemDist All
No collar Collar No collar Collar
N 85 114 77 69 345
Male sex 30/85 (35%) 47/114 (41%) 32/77 (42%) 30/69 (43%) 139/345 (40%)
Age years 79 (71 82) 76 (70 83) 79 (71 82) 79 (73 84) 78 (71 83)
Rest pain/ulcer/gangrene 80/85 (94%) 106/114 (93%) 74/77 (96%) 64/69 (93%) 324/345 (94%)
Acute ischaemia
or severe intermittent claudication
5/85 (6%) 8/114 (7%) 3/77 (4%) 5/69 (7%) 21/345 (6%)
Diabetes 28/80 (35%) 40/109 (37%) 28/76 (37%) 25/67 (37%) 121/332 (36%)
Cardiac disease 50/82 (61%) 62/110 (55%) 54/75 (72%) 39/67 (58%) 205/334 (61%)
Previous vascular surgeryb 43/81 (53%) 60/91 (66%) 45/76 (59%) 39/66 (59%) 187/314 (60%)
Pulmonary disease 9/81 (11%) 8/109 (7%) 9/74 (12%) 7/67 (10%) 33/331 (10%)
Renal disease 8/81 (10%) 9/109 (8%) 8/72 (11%) 9/66 (14%) 34/328 (10%)
Smokersc 27/77 (35%) 35/100 (35%) 21/66 (47%) 14/59 (24%) 97/302 (32%)
a Median (1st and 3rd quartile) is used for age. Numbers do not necessarily add up as full information was not available for all patients.
b Any previous vascular surgery or major amputation.
c Any regular smoking during the last five years.
750 SCAMICOSInformation was missing for three patients in the Fem-
PopBK group, leaving 199 for analysis (114 with collar) and
for four patients in the FemDist group, leaving 146 patients
for analysis (69 with collar). In total, information from 345
of 352 randomised patients was used in the analysis (98%)
(Fig. 1).
Three protocol violations occurred in the FemPopBK
group, including one patient having a suitable vein to be
used for reconstruction, one patient having a distal recon-
struction and one patient receiving a collar despite ran-
domisation to the ‘non-collar’ group. However, all patients
were analysed by intention to treat. The results were not
influenced by whether an intention to treat or a per-
protocol analysis was performed.
Patient population: baseline, operative data and
30-day complications
Table 1 shows the baseline data for the two randomised
groups (FemPopBK and FemDist) separately for patients
with and without vein collar together with overall data for
the 345 analysable patients. Table 2 shows the complica-
tions and primary patency, limb salvage and survival at 30
days for the two randomised groups (FemPopBK andTable 2 Complications and some life table data within 30 days





4/85 (5%) 12/114 (11%)
Bleeding 5/85 (6%) 5/114 (4%)
Cardiac complication 5/85 (6%) 5/114 (4%)
No complication 70/85 (82%) 82/114 (72%)
Primary patency 90 (84e97) 87 (81e93)
Limb salvage 95 (91e100) 95 (91e99)
Survival 98 (94e100) 98 (96e100)
a Categorical data is given as n/N (percent) and life table data as pFemDist) separately for patients with and without vein
collar together with data for all patients. There were no
clinically important differences between patients with and
without collar, except for primary patency in the FemDist
group, which was 15% higher in patients with a collar,
though not significant. More than one-fourth of the patients
had at least some local complication within 30 days after
surgery (Table 2). There were 8% wound complications and
a mortality rate of 4% at 30 days after surgery for the whole
group of patients.
Primary patency, secondary patency, limb salvage
and survival
In Figs. 2e5, the probability of primary patency, secondary
patency, limb salvage and survival are shown with Kaplane
Meier life table technique and the results of the log-rank
test are also given for the two randomised groups (Fem-
PopBK and FemDist) separately for patients with and
without vein collar. More than 50% of the patients were
deceased after 5 years (Fig. 5). Table 3 shows primary
patency, secondary patency, limb salvage and survival at 3
years together with the 95% CI. From the estimated primary
patency rates and with use of effective sample size,11 at 3after femoro-popliteal below-knee and femoro-distal bypass
FemDist All
No collar Collar
8/77 (10%) 4/69 (6%) 28/345 (8%)
10/77 (13%) 6/69 (9%) 26/345 (8%)
10/77 (13%) 3/69 (4%) 23/345 (7%)
47/77 (61%) 54/69 (78%) 253/345 (73%)
72 (63e83) 87 (79e95) 84 (80e88)
89 (83e97) 96 (91e100) 94 (91e96)
90 (84e98) 95 (91e100) 96 (94e98)
ercent (95% confidence interval).
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vein collar was calculated as þ2.8% to þ35% and 18% to
þ12% for the FemPopBK and FemDist groups, respectively.
However, when all time points in the KaplaneMeier life
table were evaluated, there were no statistically significant
differences between patients with and without vein collar
(primary patency: chi2 Z 3, 1 df, p Z 0.0853 and
chi2Z 1.5, 1 df, pZ 0.228; secondary patency: chi2Z 1, 1
df, pZ 0.317 and chi2Z 1.2, 1 df, pZ 0.280; limb salvage:
chi2Z 0.1, 1 df, pZ 0.757 and chi2Z 1.7, 1 df, pZ 0.187
for FemPopBK and FemDist, respectively; Figs. 2e4). Only
82 patients had a secondary patency longer than their
primary patency and the difference between secondary and
primary patency was median (1st and 3rd quartiles) 67.6 (20
and 186) days. However, for 11 patients the difference was
more than 365 days. The median (1st and 3rd quartile)
observation times were 626 (183.5 and 1111) and 363.5
(91.25 and 904.25) days for FemPopBK and FemDist,
respectively. Interaction between the factor ‘vein collar’
on the one hand and ‘small study centre (10 patientsFigure 2 Primary patency for the FemPopBK (a) and FemDist
(b) bypass groups. In the log-rank-test stratification was used
for ‘‘external support’’ as explained in ‘‘Hypotheses, power
calculation, statistics, and ethics’’. The standard error of the
KM-curves did not exceed 10% anywhere in the curves.randomised)’, ‘external support’ and ‘the 6% patients with
acute ischaemia/severe claudication’ on the other were
tested by means of Cox regression12 and no statistically
significant interactions were found (results not shown).
Discussion
The present study has failed to show any beneficial effect of
an interposed vein collar at the distal anastomosis in patients
with critical limb ischaemia operated upon with a synthetic
PTFE graft to the popliteal artery below the knee joint
(FemPopBK) or to the crural arteries (FemDist). This is true
with respect toprimarypatency, secondarypatencyaswell as
limb salvage in both groups of reconstruction.
Patients with and without vein collar compare well at
baseline with respect to co-morbidities as well as sex and
age distribution. This is true also with respect to the
localisation of the distal anastomosis (Table 1). Unfortu-
nately, the distal runoff was not registered in the different
groups of the study and such data could have further
confirmed the comparability between groups. However, theFigure 3 Secondary patency for the FemPopBK (a) and
FemDist (b) bypass groups. In the log-rank-test stratification
was used for ‘‘external support’’ as explained in ‘‘Hypotheses,
power calculation, statistics, and ethics’’. The standard error
of the KM-curves did not exceed 10% anywhere in the curves.
Figure 4 Limb salvage for the FemPopBK (a) and FemDist (b)
bypass groups. In the log-rank-test stratification was used for
‘‘external support’’ as mentioned in ‘‘Hypotheses, power
calculation, statistics, and ethics’’. The standard error of the
KM-curves did not exceed 10% anywhere in the curves.
Figure 5 Survival for all patients in the FemPopBK and
FemDist bypass groups together. The standard error did not
exceed 10% anywhere in the curve.
Table 3 Primary patency, secondary patency, limb
salvage, and survival at three years after the reconstruction
with expanded PTFE graft.
FemPopBK FemDist
Percent 95% CI n at
risk
Percent 95% CI n at
risk
Primary patency
Collar 26 18e38 15 20 11e38 7
No collar 43 33e58 15 17 9e33 6
Secondary patency
Collar 32 23e44 19 22 12e39 8
No collar 42 31e56 15 20 11e35 7
Limb salvage
Collar 64 54e75 31 59 46e76 18
No collar 61 50e74 23 44 32e61 11
Survival
Collar 60 51e73 31 66 54e82 19
No collar 67 56e81 23 53 40e72 12
752 SCAMICOSrandomisation technique ought to cancel out such possible
differences. Missing information and protocol violations
were rare. Taking the old age of the patients into consid-
eration, an acceptable follow-up rate was achieved.
Patients were recruited to the FemPopBK group in excess of
that which was required according to the power analysis,
but the study failed to recruit the stipulated number of
patients to the FemDist group. Our data are not compatible
with any advantage for the collar in the FemPopBK group at
the 3-year point in time (the whole CI is above 0%, þ2.8%
and þ35%). However, in the FemDist part of the study
(where CI is between 18% and þ12%), our data are still
compatible with clinically important better (as well as
worse) patency for the interposed cuff and this may of
course be an effect of the lower power in this part of the
study. The lack of a positive effect of the vein collar in this
group does not, however, appear to be a type II error but
rather the result of the fact that any conceivable advantageof the vein collar decreases with time (Figs. 2e4). Using the
results of this study to recalculate sample size indicates the
need of a substantial number of patients to study the effect
of a vein collar in the infra-popliteal position, which would
hardly make such a study of practical interest. Making our
results public seems reasonable and also ethical should
anyone want to perform a meta-analysis.
The main finding of the study is the lack of any improved
patency associated with the use of vein collar. In the
FemPopBK group, there was, in fact, a numerically detri-
mental, but statistically not significant, effect of the vein
collar with respect to both primary and secondary
patencies. This is also supported by the estimated CI of the
difference in primary patency rate at 3 years for patients
with and without vein collar which did not include any
higher patency for the vein collar group. The differences
between primary and secondary patency were small. It
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little advantage to offer to the patient. However, alterna-
tively, this could also be accounted for by reluctance for re-
intervention and 11 patients gained more than a year of
further patency with a re-intervention. In the FemDist
group, there was again, not statistically significant,
a numerically improved patency with a vein collar during
the second and part of the third year of follow-up (Fig. 2(b)
and 3(b)). Although speculative in this study, this may be an
effect of the suggested decreased formation of pseudo-
intima with use of the vein collar15 or possibly an effect
of more space being available in the vein collar to accom-
modate the bulk of pseudo-intima. Another suggested
beneficial effect is a change in the haemodynamic forces,
which has stimulated to the design of PTFE grafts with
a prefabricated widened anastomotic part.16 However, the
effect (true or false) diminishes with time and, overall, no
statistically significant effect has been established for
patency. Further, the primary patencies with use of grafts
with a prefabricated widened anastomotic part16 are very
similar to those found in the present study and, to the best
of our knowledge, the advantage of such grafts have not
been proved or tested in any randomised study.
A further suggested advantage with the vein collar is
that the recipient artery may be spared from propagation
of the thrombotic process after an occlusion.17 Such
mechanism may have some support, although speculative,
by the fact that the limb salvage rate is numerically better
in patients with vein collars independent of the site of the
distal anastomosis despite the fact that patency is numer-
ically worse for those with vein collars in the FemPopBK
group. However, again, no statistically significant overall
effects were found with respect to limb salvage.
The Joint Vascular Research Group (JVRG) of UK has
published two reports17,18 of their study of the vein collar
and its effect with respect to patency and limb salvage in the
above-knee and below-knee position. The first publication
reported an improved patency and a tendency towards
better limb salvage in the below-knee position. In the
second publication (with a median follow-up time of 622
days), the improved patency was confirmed in the below-
knee position but no effect was established with respect to
limb salvage, albeit it appears as if the more distal recon-
structions were excluded from the analysis in that report. It
is not immediately evident how the discrepancies between
the JVRG study and the present one should be explained.
However, the patient population showed some differences.
The patients in the present study were a decade older,
probably explaining the higher proportion of females in this
study (60% compared with 40% in the JVRG study). Another
important difference was, however, the much higher
proportion of distal bypasses in the present study. The
present patient population is rather typical for Swedish
patients with critical limb ischaemia e 36% had diabetes,
61% cardiac disease, 60% had undergone previous vascular
surgery or amputation and 32% were smokers (Table 1).
These differences between the populations may explain at
least part of the different results. However, is it likely that
the vein collar differs in effect between younger males and
older females with thinner arteries and failing hearts?
Finally, the femoro-popliteal below-knee or more distal
reconstruction to the crural arteries with synthetic graft isnot a simple task in this frail group of patients with an
abundance of co-morbidities and considerable age as
illustrated by the high complication rates and mortality.
This is especially so in light of the rather modest chances of
long-term success with respect to the patency of the
reconstructions with only one-fifth of the reconstructions
patent at 5 years. An individual patient might well be
better off with primary amputation, if necessary, and
prompt rehabilitation.1 Alternatively, in individual
patients, it may be wise to resort to more lenient endo-
vascular methods if this is technically feasible. At least this
may not burden the patient with complications to the same
degree as open surgery does.19 Whether or not these
methods give results comparable to bypass surgery in the
group of patients included in this study, however, has yet to
be shown in a randomised trial. In the Basil study,20
patients with critical ischaemia scheduled for an infra-
inguinal procedure were randomised between bypass and
endovascular technique. The main conclusion was that fit
patients did better on long-term basis with a bypass,
whereas endovascular technique appeared to suit not-so-
fit patients better. However, there are large differences
between the patient population in the Basil study and in
the design of that study when compared to the present one:
predominantly male patients, only one-third of the
patients had had previous vascular surgery, one-third of the
patients had an above-knee lesion, of the patients with
bypass three-fourths were reconstructed with a saphenous
vein. Further, the Basil study did not report on patency or
limb salvage, but only on the combined end-point ampu-
tation-free survival and on general survival. Therefore, it is
rather questionable if the findings of the Basil study are
applicable to the population of the present study.
However, the mortality of 60% at 3 years in both studies
may indicate that the general burden of disease is
approximately similar in the two studies.
In conclusion, in an elderly, predominately female pop-
ulation with critical limb ischaemia and with a substantial
share of cardiovascular disease, the use of an anastomotic
vein collar did not influence patency or limb salvage when
a PTFE graft was used for below-knee reconstructive
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10); Skelleftea˚ (Martin Bjo¨rck, 11); Sko¨vde (Lars Brunes, 9);
Stockholm-St Go¨ran (Gunnar Johansson, 13); Stockholm-
So¨dersjukhuset (Lars Karlstro¨m, 6); Trollha¨ttan-NA¨L (Per-
Erland Tornell, 10); Uppsala (Christer Ljungman, 7); Va¨stervik
(A˚ke Aldman, 10); Va¨stera˚s (Ola Forsberg, 30); Va¨xjo¨ (Hilding
Bjo¨rkman, 14); O¨rebro (Berndt Arfvidsson,4); O¨stersund
(Thomas Bohlin, 4).
Denmark
Aalborg (Jørgen Sloth Nielsen, 2); Copenhagen-
Rigshospitalet (Torben Schroeder, 15); Kolding (Morten
Stahl Madsen, 1).
Excellent secretarial and organisational help by Liselott
Hillman e study secretary e and Bodil Ejnar e study nurse
e at the study office in Norrko¨ping, Sweden, is thankfully
acknowledged.
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